Tarsus Pharmaceuticals (NASDAQ: TARS ) is now two years into the launch of Xdemvy (lotilaner) for Demodex blepharitis, and while sales have passed $100M per quarter, so has SG&A. In May, I rated TARS a buy, noting their "Get Big Fast" approachScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...